Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages

Journal of Cellular Physiology

Volumn 227, Issue 5, 2012, Pages 2117-2122

  Souza, Laura L ^a   Costa Neto, Claudio M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MAS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN I; ANIMALS; CELLS, CULTURED; CYTOKINES; HEK293 CELLS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SRC-FAMILY KINASES;

EID: 82755169678     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22940     Document Type: Article

References (64)

1. Benter IF, Diz DI, Ferrario CM. 1995. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 26: 1138-1144.
2. Brasier AR. 2010. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 86: 211-218.
3. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS. 2000. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212: 155-169.
4. Brosnihan KB, Li P, Ferrario CM. 1996. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523-528.
5. Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. 1994. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. J Vasc Med Biol 5: 129-137.
6. Da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, Bretas TL, Bader M, de Sousa LP, da Silva TA, dos Santos RA, Simões E, Silva AC, Teixeira MM. 2010. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 185: 5569-5576.
7. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. 2000. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472.
8. Dilauro M, Burns KD. 2009. Angiotensin-(1-7) and its effects in the kidney. Sci World J 9: 522-535.
9. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. 2003. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 26: 691-697.
10. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9.
11. Esteban V, Ruperez M, Vita JR, López ES, Mezzano S, Plaza JJ, Egido J, Ruiz-Ortega M. 2003. Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl 86: S33-S38.
12. Esteban V, Lorenzo O, Rupérez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M. 2004. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15: 1514-1529.
13. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M, Walther T. 2009. Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS ONE 4: e5406.
14. Ferrario CM. 2006. Angiotensin-converting enzyme 2 and angiotensin-(1-7): An evolving story in cardiovascular regulation. Hypertension 47: 515-521.
15. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. 1997. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541.
16. Ferreira AJ, Santos RA. 2005. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 38: 499-507.
17. Ferreira AJ, Castro CH, Guatimosim S, Almeida PW, Gomes ER, Dias-Peixoto MF, Alves MN, Fagundes-Moura CR, Rentzsch B, Gava E, Almeida AP, Guimarães AM, Kitten GT, Reudelhuber T, Bader M, Santos RA. 2010. Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. Ther Adv Cardiovasc Dis 4: 83-96.
18. Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Künzler P, Enseleit F, Périat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F. 2008. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117: 2262-2269.
19. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. 2003. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: Roles of the receptor complex. Pharmacol Ther 100: 171-194.
20. Gallagher PE, Tallant EA. 2004. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25: 2045-2052.
21. 3 (neurokinin B) receptors-Identification of domains determining the binding specificity of tachykinin. J Biol Chem 268: 7893-7898.
22. Giani JF, Muñoz MC, Mayer MA, Veiras LC, Arranz C, Taira CA, Turyn D, Toblli JE, Dominici FP. 2010. Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats. Am J Physiol Heart Circ Physiol 298: H1003-H1013.
23. Gomes ER, Lara AA, Almeida PW, Guimarães D, Resende RR, Campagnole-Santos MJ, Bader M, Santos RA, Guatimosim S. 2010. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3', 5'-cyclic monophosphate-dependent pathway. Hypertension 55: 153-160.
24. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. 2007. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-H742.
25. Guha M, Mackman N. 2001. LPS induction of gene expression in human monocytes. Cell Signal 13: 85-94.
26. Hagiwara S, Iwasaka H, Matumoto S, Hidaka S, Noguchi T. 2009. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med 37: 626-633.
27. Handa RK, Ferrario CM, Strandhoy JW. 1996. Renal actions of angiotensin-(1-7): In vivo and in vitro studies. Am J Physiol 270: F141-F147.
28. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, Egido J. 1997. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532-1541.
29. Holst O, Ulmer AJ, Brade H, Flad HD, Rietschel ET. 1996. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol Med Microbiol 16: 83-104.
30. Iwai M, Horiuchi M. 2009. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 32: 533-536.
31. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. 2005. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363.
32. Kang JL, Lee HW, Kim HJ, Lee HS, Castranova V, Lim CM, Koh Y. 2005. Inhibition of SRC tyrosine kinases suppresses activation of nuclear factor-kappaB, and serine and tyrosine phosphorylation of IkappaB-alpha in lipopolysaccharide-stimulated raw 264.7 macrophages. J Toxicol Environ Health A 68: 1643-1662.
33. Kranzhofer R, Browatzki M, Schmidt J, Kübler W. 1999. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 257: 826-828.
34. Larrayoz IM, Pang T, Benicky J, Pavel J, Sánchez-Lemus E, Saavedra JM. 2009. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes. J Hypertens 27: 2365-2376.
35. Lee YG, Lee WM, Kim JY, Lee JY, Lee IK, Yun BS, Rhee MH, Cho JY. 2008. Src kinase-targeted anti-inflammatory activity of davallialactone from Inonotus xeranticus in lipopolysaccharide-activated RAW264.7 cells. Br J Pharmacol 154: 852-863.
36. Leu TH, Charoenfuprasert S, Yen CK, Fan CW, Maa MC. 2006. Lipopolysaccharide-induced c-Src expression plays a role in nitric oxide and TNFalpha secretion in macrophages. Mol Immunol 43: 308-316.
37. Liu E, Yang S, Xu Z, Li J, Yang W, Li G. 2010. Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. Regul Pept 162: 73-78.
38. Marchesi C, Paradis P, Schiffrin EL. 2008. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29: 367-374.
39. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM, Reudelhuber TL. 2008. Angiotensin (1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319-1326.
40. Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D. 1995. Expression of the mouse and rat Mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 357: 27-32.
41. Napolitani G, Bortoletto N, Racioppi L, Lanzavecchia A, D'Oro U. 2003. Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol 33: 2832-2841.
42. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T. 1999. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 17: 537-545.
43. Oliveira L, Costa-Neto CM, Nakaie CR, Schreier S, Shimuta SI, Paiva AC. 2007. The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure. Physiol Rev 87: 565-592.
44. Pham H, Chong B, Vincenti R, Slice LW. 2008. Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells. J Cell Physiol 214: 96-109.
45. Ren Y, Garvin JL, Carretero OA. 2002. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39: 799-802.
46. Ruiz-Ortega M, Lorenzo O, Rupérez M, König S, Wittig B, Egido J. 2000. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: Molecular mechanisms. Circ Res 86: 1266-1272.
47. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J. 2001. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329.
48. Ruiz-Ortega M, Esteban V, Rupérez M, Sánchez-López E, Rodríguez-Vita J, Carvajal G, Egido J. 2006. Renal and vascular hypertension-induced inflammation: Role of angiotensin II. Curr Opin Nephrol Hypertens 15: 159-166.
49. Sanchez-Lemus E, Murakami Y, Larrayoz-Roldan IM, Moughamian AJ, Pavel J, Nishioku T, Saavedra JM. 2008. Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology 149: 5177-5188.
50. Sanchez-Lemus E, Benicky J, Pavel J, Saavedra JM. 2009. In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav Immun 23: 945-957.
51. Santos RA, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. 1992. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 19: II56-II61.
52. Santos RA, Campagnole-Santos MJ, Andrade SP. 2000. Angiotensin-(1-7): An update. Regul Pept 91: 45-62.
53. Santos RA, Simoes E, Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. 2003. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263.
54. Schieffer B, Bünte C, Witte J, Hoeper K, Böger RH, Schwedhelm E, Drexler H. 2004. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44: 362-368.
55. Smolinska MJ, Horwood NJ, Page TH, Smallie T, Foxwell BM. 2008. Chemical inhibition of Src family kinases affects major LPS-activated pathways in primary human macrophages. Mol Immunol 45: 990-1000.
56. Souza PP, Fukada SY, Cunha FQ, Costa CA, Costa-Neto CM. 2007. Regulation of angiotensin II receptors levels during rat induced pulpitis. Regul Pept 140: 27-31.
57. Strawn WB, Ferrario CM, Tallant EA. 1999. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33: 207-211.
58. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. 2003. Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900.
59. Tallant EA, Clark MA. 2003. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579.
60. Tallant EA, Diz DI, Ferrario CM, 1999. State-of-the-art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34: 950-957.
61. Tallant EA, Ferrario CM, Gallagher PE. 2005. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-H1566.
62. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. 2000. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243.
63. Van der Wouden EA, Ochodnicky P, van Dokkum RP, Roks AJ, Deelman LE, de Zeeuw D, Henning RH. 2006. The role of angiotensin(1-7) in renal vasculature of the rat. J Hypertens 24: 1971-1978.
64. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. 1992. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19: 692-696.